Wang Boyang, Zhang Dingfan, Zhang Tingyu, Sutcharitchan Chayanis, Hua Jianlin, Hua Dongfang, Zhang Bo, Li Shao
Institute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, FIT 1-115, Beijing, 100084, China.
Tianjin Oriental HuaKang Pharmaceutical Technology Development Co., Ltd, Tianjin, 300457, China.
Chin Med. 2023 Jul 24;18(1):88. doi: 10.1186/s13020-023-00781-1.
The purpose of this study is to reveal the mechanism of action of Yi Qi Tong Qiao Pill (YQTQP) in the treatment of allergic rhinitis (AR), as well as establish a paradigm for the researches on traditional Chinese medicine (TCM) from systematic perspective.
Based on the data collected from TCM-related and disease-related databases, target profiles of compounds in YQTQP were calculated through network-based algorithms and holistic targets of TQTQP was constructed. Network target analysis was performed to explore the potential mechanisms of YQTQP in the treatment of AR and the mechanisms were classified into different modules according to their biological functions. Besides, animal and clinical experiments were conducted to validate our findings inferred from Network target analysis.
Network target analysis showed that YQTQP targeted 12 main pathways or biological processes related to AR, represented by those related to IL-4, IFN-γ, TNF-α and IL-13. These results could be classified into 3 biological modules, including regulation of immune and inflammation, epithelial barrier disorder and cell adhesion. Finally, a series of experiments composed of animal and clinical experiments, proved our findings and confirmed that YQTQP could improve related symptoms of AR, like permeability of nasal mucosa epithelium.
A combination of Network target analysis and the experimental validation indicated that YQTQP was effective in the treatment of AR and might provide a new insight on revealing the mechanism of TCM against diseases. Trial registration Name of the registry: Chinese Clinical Trial Registry: Trial registration number: ChiCTR-TRC-13,003,137: Date of registration: Registered 29 March 2013 - Retrospectively registered: URL of trial registry record: https://www.chictr.org.cn/showproj.html?proj=6422 .
本研究旨在揭示益气通窍丸（YQTQP）治疗变应性鼻炎（AR）的作用机制，并从系统角度建立中药研究的范例。
基于从中医相关和疾病相关数据库收集的数据，通过基于网络的算法计算YQTQP中化合物的靶点谱，并构建YQTQP的整体靶点。进行网络靶点分析以探索YQTQP治疗AR的潜在机制，并根据其生物学功能将这些机制分类为不同模块。此外，进行动物和临床实验以验证我们从网络靶点分析中推断出的结果。
网络靶点分析表明，YQTQP靶向12条与AR相关的主要通路或生物学过程，以与IL-4、IFN-γ、TNF-α和IL-13相关的通路或过程为代表。这些结果可分为3个生物学模块，包括免疫和炎症调节、上皮屏障紊乱和细胞黏附。最后，一系列由动物和临床实验组成的实验证明了我们的发现，并证实YQTQP可以改善AR的相关症状，如鼻黏膜上皮的通透性。
网络靶点分析与实验验证相结合表明，YQTQP治疗AR有效，并可能为揭示中药治疗疾病的机制提供新的见解。试验注册 注册机构名称：中国临床试验注册中心；试验注册号：ChiCTR-TRC-13,003,137；注册日期：2013年3月29日 - 回顾性注册；试验注册记录的网址：https://www.chictr.org.cn/showproj.html?proj=6422 。
Zotero 插件
